Tissue Regenix to attend JPMorgan Healthcare Event

-----

Tissue Regenix Group plc

Tissue Regenix to attend 32nd Annual J.P. Morgan Healthcare Conference

YORK, 19 December 2013 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Group"), the regenerative medical devices company, today announces that Antony Odell, Managing Director of Tissue Regenix, will be attending the 32nd Annual J.P. Morgan Healthcare Conference, to be held on 13-16 January in San Francisco.

ENDS

For Further Information

Tissue Regenix Group plc: +44 19 0443 5176

Antony Odell

Newgate Communications: +44 207 6806550

Andrew Jones

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularization ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercializes academic research conducted by our partners around the World.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States- 'Tissue Regenix Wound Care Inc.', as part of its commercialization strategy for its dCELL® technology platform.